Eton Pharmaceuticals (ETON) Long-Term Deferred Tax (2018 - 2024)

Eton Pharmaceuticals (ETON) has 6 years of Long-Term Deferred Tax data on file, last reported at $404000.0 in Q4 2024.

• For the quarter ending Q4 2024, Long-Term Deferred Tax rose 139.05% year-over-year to $404000.0; the trailing twelve-month figure through Dec 2024 stood at $404000.0 (up 139.05% YoY), and the FY2024 full-year result was $404000.0, up 139.05% from the prior year.
• Long-Term Deferred Tax improved to $404000.0 in Q4 2024, from $169000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $21.6 million in Q4 2022 to a low of $169000.0 in Q4 2023.
• A 4-year average of $10.2 million and a median of $9.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax sank 99.22% in 2023 and jumped 139.05% in 2024, its largest moves.
• Tracing ETON's Long-Term Deferred Tax over 4 years: stood at $18.5 million in 2021, then increased by 16.63% to $21.6 million in 2022, then slumped by 99.22% to $169000.0 in 2023, then surged by 139.05% to $404000.0 in 2024.
• Business Quant data shows ETON's Long-Term Deferred Tax at $404000.0 in Q4 2024, $169000.0 in Q4 2023, and $21.6 million in Q4 2022.